Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of myeloma cast nephropathy (MYRE)
2009-017926-38Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib in multiple myeloma (MM), light chain cast nephropathy (LCCN) and acute kidney failure (AKF) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary renal function outcome. Started Jun 2010; status: active.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)light chain cast nephropathy (LCCN)acute kidney failure (AKF)
Beyond the preview
Go deeper on 2009-017926-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017926-38.